Germany's Scholz pledges support for pharmaceutical industry [Yahoo! Finance]
DAIICHI SANKYO S/ADR (DSNKY)
NASDAQ:AMEX Investor Relations:
daiichisankyo.com/media_investors/investor_relations/index.html
Company Research
Source: Yahoo! Finance
Scholz spoke at the laying of the foundation stone on Thursday for a €300 million ($320 million) new research centre at German chemical and pharmaceutical firm Merck's headquarters in the western German city of Darmstadt, located south of Frankfurt. The chancellor called the expansion project a "commitment to Germany as a strong location for pharmaceuticals, industry and research." The centre is scheduled to open in three years. "Investments such as those made by Merck here at the Darmstadt headquarters make exceptional economic, medical and scientific sense," said Scholz. The chancellor noted that Merck isn't the only firm from the sector to invest heavily in Germany, pointing for example to plans by the US pharmaceutical company Eli Lilly to build a €2.3 billion plant as well as similar plans from Switzerland's Roche and Japan's Daiichi Sankyo. "These are investments on a scale that we have not seen in Germany for a long time," said Scholz. "As the German government, we w
Show less
Read more
Impact Snapshot
Event Time:
DSNKY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DSNKY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DSNKY alerts
High impacting DAIICHI SANKYO S/ADR news events
Weekly update
A roundup of the hottest topics
DSNKY
News
- Fight Colorectal Cancer Launches ChatCRC: An AI-Powered Chatbot Revolutionizing Colorectal Cancer Support [Yahoo! Finance]Yahoo! Finance
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow [Yahoo! Finance]Yahoo! Finance
- ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 TrialBusiness Wire
- FDA Roundup: April 9, 2024 [Yahoo! Finance]Yahoo! Finance
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors [Yahoo! Finance]Yahoo! Finance